Pharmacokinetics In Compromised Animals

Pharmacokinetic alterations become prevalent when animals have reduced organ function, resulting in unintended systemic compound exposure and elevated presentation of side effects. Conducting the in-life phase of a PK study in compromised animals provides data that is reliable and predictive of how the compound will act in a disease setting.

Mechanistically Relevant Pharmacodynamics

PBI’s collective years of pharmaceutical discovery and development in the cardiovascular, renal, hepatic and pulmonary disease areas can help guide PD experiments to the best model for target engagement. In conjunction with reliable biomarkers, acute PD models can be run as functional screens to give the breadth and efficiency necessary for our clients’ drug discovery efforts.